Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Trial de viabilidade tradicional Perqdisc.

4 de novembro de 2026 atualizado por: Spinal Stabilization Technologies

Um estudo de viabilidade tradicional multicêntrico do implante artificial Perqdisc no tratamento da dor nas costas discogênica de nível único.

This is a traditional feasibility study (TFS) study to evaluate the safety and effectiveness of the PerQdisc. The study is prospective, multicenter, and open label.

After a screening period, qualified participants will be enrolled and treated with the PerQdisc. Patients will not be blinded to their treatment. Participants will then complete the safety follow-up period.

Visão geral do estudo

Status

Recrutamento

Intervenção / Tratamento

Descrição detalhada

The proposed investigation is a multicenter, prospective, traditional feasibility study of the PerQdisc. A minimum of N=5 subjects will be enrolled. Subjects will be enrolled in approximately 2 sites. Data analyses including all enrolled subjects meeting specific criteria will be submitted to the FDA to support a pivotal trial and used in trial planning. This study will evaluate the safety and effectiveness of the PerQdisc device in the treatment of single level discogenic back pain caused by degenerative disc disease (DDD) (L1 to L5).

Tipo de estudo

Intervencional

Inscrição (Estimado)

5

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Arizona
      • Glendale, Arizona, Estados Unidos, 85308
        • Retirado
        • Hope Research Institute
      • Phoenix, Arizona, Estados Unidos, 85032
        • Retirado
        • HOPE Research Institute
      • Phoenix, Arizona, Estados Unidos, 85023
        • Recrutamento
        • The CORE Institute
        • Contato:
        • Investigador principal:
          • Ali Araghi, DO
      • Scottsdale, Arizona, Estados Unidos, 85251
        • Recrutamento
        • HonorHealth Research & Innovation Institute
        • Contato:
        • Investigador principal:
          • Luis Tumialan, MD
    • Florida
      • Miami, Florida, Estados Unidos, 33136
        • Recrutamento
        • University of Miami
        • Investigador principal:
          • Michael Wang, MD
        • Contato:
    • Idaho
      • Coeur d'Alene, Idaho, Estados Unidos, 83854
        • Recrutamento
        • Axis Spine Center
        • Investigador principal:
          • Roland Kent, MD
        • Contato:
    • Indiana
      • Carmel, Indiana, Estados Unidos, 46032
        • Recrutamento
        • Indiana Spine Group
        • Contato:
        • Investigador principal:
          • Paul Kraemer, MD
    • Louisiana
      • Shreveport, Louisiana, Estados Unidos, 71101
        • Recrutamento
        • Spine Institute of Louisiana
        • Contato:
        • Investigador principal:
          • Pierce Nunley, MD
    • Oklahoma
      • Oklahoma City, Oklahoma, Estados Unidos, 73159
        • Retirado
        • SonoSpine

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

22 anos a 70 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Skeletally mature male or female subjects aged 22-70 (inclusive).
  2. Subject has a primary diagnosis of single level discogenic back pain caused by degenerative disc disease (L1 to L5) identified via MRI.
  3. Subject has an intact annulus (as determined by MRI) and endplates (as determined by MRI and X-ray) at the level to be treated.
  4. Subject must have failed to respond to a minimum of 6 months of conservative treatment for their back pain (e.g., physical therapy, medications, injections, ablations, lifestyle changes, etc.).
  5. Subject has a low back pain VAS ≥40 mm (4 cm).
  6. Subject has adequate disc height (≥6mm measured at the center of the disc) at the level to be treated. [As measured by the investigator]
  7. Subject is psychosocially, mentally and physically able and willing to fully comply with this protocol including adhering to follow-up schedule and requirements and filling out forms.
  8. Subject has read and understands the IRB approved informed consent document prior to signing and dating the document and before the initiation of any study-related procedures
  9. Subject is appropriate candidate for the PerQdisc surgical approach [as defined in the surgical technique guide].

Exclusion Criteria:

  1. Subject has symptomatic degenerative disc disease at more than one lumbar level

  2. Subject has had a prior spinal fusion in the lumbar or thoracic intervertebral spaces.

  3. Subject has had a prior SI-joint fusion.

  4. Subject has a spinal cord stimulator.

  5. Subject has had any prior lumbar spine surgery (instrumented or non-instrumented)

  6. Subject has a significant disc herniation at the level to be treated. Significant is defined as a large, extruded herniation that creates a risk for expulsion.

  7. Subject has congenital moderate or severe spinal stenosis or epidural lipomatosis.

  8. Subject has spondylolisthesis (antero- or retrolisthesis) in static X-ray ≥3 mm [measured via neutral lateral x-ray]

  9. Subject has ≥4 mm dynamic spondylolisthesis [measured via flexion/extension x-rays]

  10. Subject has > 20 degree range of motion at the index level [measured via flexion/extension x-rays]

  11. Subject has a history of any invasive malignancy (except non-melanoma skin cancer) unless treated with curative intent and there have been no clinical signs or symptoms of malignancy for at least 5 years (in particular, spinal tumors).

  12. Subject has an active systemic infection or infection at the operative site.

  13. Subject has evidence of symptomatic facet joint degeneration or disease where the investigator feels the facet is a major contributor to the subject's pain as diagnosed by injection and/or imaging.

  14. Subject has a known allergy to silicone or barium sulfate.

  15. Subject has been diagnosed with fibromyalgia, hepatitis, rheumatoid arthritis, lupus erythematosus, AIDs, ARC, HIV, or an autoimmune disease that affects the musculoskeletal system.

  16. Subject has been diagnosed with Paget's disease, osteomalacia or any other metabolic bone disease.

  17. Subject has current or recent history (defined ≤ 1 year prior to screening) of substance abuse (alcoholism and/or narcotic addiction) using standard medical definitions of DSM-5

  18. Subject has morbid obesity defined as a body mass index (BMI) > 40.

  19. Subject participated in an investigational drug or another medical device study within the last 30 days prior to surgery.

  20. Subject has Osteoporosis, defined as a T-score ≤ -2.5.

    1. An existing DEXA is allowed if completed within 6 months of subject surgery.
    2. For all subjects without an existing DEXA, the SCORE/MORES will be utilized to screen if a DEXA scan is indicated. If SCORE/MORES value ≥ 6, then a DEXA scan is required.
  21. Female subjects who are pregnant or are trying to become pregnant during the course of the trial.

  22. Subject has diabetes mellitus (Type 1 or 2) requiring daily insulin management.

  23. Subject belongs to a vulnerable population or has a condition such that his/her ability to provide informed consent, comply with follow-up requirements, or provide self-assessments is compromised (e.g. developmentally disabled, prisoner, chronic alcohol/ substance abuser)

  24. Subject is currently receiving worker's compensation or is involved in any litigation for medical negligence, trauma, or worker's compensation.

  25. Subject has lumbar scoliosis > 10 degrees at index level.

  26. Subject has a large, rectangular or irregularly shaped Schmorl's node with an associated active inflammatory process (Modic I changes).

  27. Subject has motion of < 3 degrees on pre-operative lateral flexion/extension radiographs at index level.

  28. Subject has opioid medication usage > 60 MME (morphine milligram equivalent)/day or change in opioid prescription within 60 days of surgery.

  29. Subject has a preoperative VAS right or left leg pain score > the preoperative VAS Back score.

  30. Subject has a history of vertebral fractures in the lumbar spine.

  31. Subject has evidence of severe compression of cauda equina.

  32. Subject is on chronic anticoagulation therapy due to a bleeding disorder and is unable to safely stop anticoagulants or has taken anticoagulants within 3 days prior to procedure.

  33. Subject has low back pain (LBP) of non-spinal or unknown etiology.

  34. Subject is unable to undergo X-ray, MRI, or other radiographic assessments, including discography.

  35. Subject has a degenerative muscular or neurological condition that would interfere with evaluation of outcomes, including but not limited to spinal disease (not at index level), Parkinson's disease, amyotrophic lateral sclerosis (ALS), or multiple sclerosis.

  36. Subject has, in the opinion of the investigator, a behavioral, cognitive, social or medical problem that may interfere with the assessment of the safety or effectiveness of the device.

  37. In the opinion of the investigator the subject has a major psychiatric disorder that may interfere with the assessment of the safety or effectiveness of the device.

  38. Subject has myelopathy.

  39. Subject has primarily leg pain with associated nerve root compression, in the opinion of the investigator.

  40. Subject has an annular defect greater than 6mm that extends from the interior of the disc to the outer margin of the annulus as evaluated on MRI.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: PerQdisc

The PerQdisc device is the first in a new category of contained in-situ filled and then cured lumbar spinal implant. The PerQdisc is intended to replace the nucleus pulposus in a single lumbar disc level, preserve motion and alleviate pain. The PerQdisc is a silicone membrane (barrier membrane) configured to be filled with a room temperature vulcanizing silicone (RTVS) that will cure within minutes, resulting in a final shape that conforms to the nucleus space created by the surgical removal of the diseased or damaged nucleus pulposus.

PerQdisc Artificial Implant

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Clinical Composite Success
Prazo: 6 Months

Clinical composite success is defined as improvement in pain and absence of qualified safety events.

6 Months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
ODI
Prazo: 6 Months

ODI 15-point responder at Month 6

6 Months
VAS Back
Prazo: 6 Months

VAS Back pain 20mm responder at Month 6

6 Months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

10 de janeiro de 2025

Conclusão Primária (Estimado)

30 de setembro de 2027

Conclusão do estudo (Estimado)

31 de março de 2030

Datas de inscrição no estudo

Enviado pela primeira vez

28 de fevereiro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

28 de fevereiro de 2025

Primeira postagem (Real)

6 de março de 2025

Atualizações de registro de estudo

Última Atualização Postada (Real)

9 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

4 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • DISCPAIN1 TFS

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Sim

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever